HIV-1 Infection Clinical Trials

A listing of 3 HIV-1 Infection clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

HIV-1 Infection

1 - 3 of 3

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 3 active clinical trials seeking participants for HIV-1 Infection research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.

Featured Trial

Project Thrive: An HIV Study For Older Adults

Recruiting

Aged 50+ and living with HIV in a rural area? Participate in a research study evaluating programs delivered to you at home. The study requires completing 4 surveys from home over 1 year. You may also be invited to participate in and share your views on new programs. Compensation for time provided (up to $400).

Conditions:

HIV

HIV Infections

HIV Infection

HIV/AIDS

HIV-1 Infection

Learn More

* Compensation for time may be available

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349

Recruiting

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/23/2024

Locations: Pueblo Family Physicians ( Site 5674), Phoenix, Arizona +64 locations

Pueblo Family Physicians ( Site 5674), Phoenix, Arizona

Pacific Oaks Medical Group ( Site 5681), Beverly Hills, California

Ruane Clinical Research Group, Inc ( Site 5658), Los Angeles, California

Washington Health Institute ( Site 5689), Washington, District of Columbia

Midway Immunology and Research Center ( Site 5657), Fort Pierce, Florida

AHF South Beach ( Site 5663), Miami Beach, Florida

AHF The Kinder Medical Group ( Site 5672), Miami, Florida

Orlando Immunology Center ( Site 5654), Orlando, Florida

CAN Community Health - Sarasota ( Site 5668), Sarasota, Florida

Triple O Research Institute, P.A ( Site 5666), West Palm Beach, Florida

Atlanta I.D. Group ( Site 5680), Atlanta, Georgia

Metro Infectious Diseases Consultants L.L.C. ( Site 5653), Decatur, Georgia

Mercer University, Department of Internal Medicine ( Site 5655), Macon, Georgia

Rush University Medical Center-Infectious Disease ( Site 5671), Chicago, Illinois

University of Illinois at Chicago-Project WISH ( Site 5685), Chicago, Illinois

Howard Brown Health Center-Clinical Research ( Site 5665), Chicago, Illinois

Be Well Medical Center ( Site 5650), Berkley, Michigan

Henry Ford Hospital ( Site 5667), Detroit, Michigan

KC CARE Health Center-Clinical Trials ( Site 5670), Kansas City, Missouri

Jubilee Clinical Research ( Site 5679), Las Vegas, Nevada

Las Vegas Research Center ( Site 5691), Las Vegas, Nevada

ID Care ( Site 5676), Hillsborough, New Jersey

Saint Michael's Medical Center ( Site 5682), Newark, New Jersey

Jacobi Medical Center ( Site 5683), Bronx, New York

Columbia University Irving Medical Center-Division of Infectious Diseases ( Site 5688), New York, New York

Atrium Health Infectious Disease Kenilworth - Charlotte ( Site 5675), Charlotte, North Carolina

Regional Center for Infectious Diseases ( Site 5687), Greensboro, North Carolina

University of Cincinnati Medical Center-Infectious Diseases - Outpatient ( Site 5662), Cincinnati, Ohio

Central Texas Clinical Research ( Site 5661), Austin, Texas

St Hope Foundation ( Site 5659), Bellaire, Texas

Prism Health North Texas, Oak Cliff Health Center ( Site 5660), Dallas, Texas

North Texas Infectious Diseases Consultants, P.A ( Site 5651), Dallas, Texas

Texas Centers for Infectious Disease Associates ( Site 5656), Fort Worth, Texas

DCOL Center for Clinical Research ( Site 5664), Longview, Texas

Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 5955), Temuco, Araucania

Clinica Universidad Catolica del Maule ( Site 5954), Talca, Maule

Biomedica Research Group-Infectology ( Site 5951), Santiago, Region M. De Santiago

Espacio Eme ( Site 5952), Santiago, Region M. De Santiago

Centro de Investigacion Clinicadela Universidad Catolica ( Site 5953), Santiago, Region M. De Santiago

Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 5950), Santiago, Region M. De Santiago

Rambam Health Care Campus-Institute of Allergy, Clinical Immunology, ( Site 6751), Haifa, Not set

Hadassah Medical Center-Infecious Disease ( Site 6752), Jerusalem, Not set

Sheba Medical Center-HIV unit ( Site 6753), Ramat Gan, Not set

Sourasky Medical Center ( Site 6754), Tel Aviv, Not set

National Hospital Organization Nagoya Medical Center ( Site 6953), Nagoya, Aichi

Tokyo Medical University Hospital ( Site 6954), Shinjuku-ku, Tokyo

Center Hospital of the National Center for Global Health and Medicine ( Site 6951), Shinjyuku-ku, Tokyo

National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 69, Osaka, Not set

Ponce Medical School Foundation Inc. ( Site 7452), Ponce, Not set

Clinical Research Puerto Rico ( Site 7450), San Juan, Not set

HOPE Clinical Research ( Site 7451), San Juan, Not set

Josha Research ( Site 6652), Bloemfontein, Free State

Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 6654), Johannesburg, Gauteng

Ezintsha-Clinical Research Site ( Site 6656), Johannesburg, Gauteng

Wentworth Hospital ( Site 6653), Durban, Kwazulu-Natal

Qhakaza Mbokodo Research Clinic ( Site 6659), Ladysmith, Kwazulu-Natal

Madibeng Centre for Research ( Site 6660), Brits, North-West

Family Clinical Research Unit (Fam-Cru)-Adult Infectious Diseases ( Site 6657), Cape Town, Western Cape

Desmond Tutu Health Foundation ( Site 6651), Cape Town, Western Cape

Be Part Yoluntu Centre ( Site 6650), Paarl, Western Cape

HIV Netherlands Australia Thailand Research Collaboration ( Site 7851), Bangkok, Krung Thep Maha Nakhon

Faculty of Medicine Siriraj Hospital-Preventive and social ( Site 7850), Bangkok, Krung Thep Maha Nakhon

Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 7852, Chiang Mai, Not set

Southmead Hospital ( Site 7952), Bristol, Bristol, City Of

King's College Hospital ( Site 7950), London, London, City Of

Conditions: HIV-1 Infection

Learn More ›

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

NCT02881320

Recruiting

The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide FDC in adolescents and children with HIV-1.

Gender:

All

Ages:

Between 1 month and 17 years

Trial Updated:

04/05/2024

Locations: Children's National Health System, Washington, District of Columbia +25 locations

Children's National Health System, Washington, District of Columbia

Midway Immunology and Research Center, Fort Pierce, Florida

University of Florida Health, Gainesville, Florida

USF Clinic at Children's Medical Services (study visits and drug storage), Tampa, Florida

Grady Health System Ponce Center Family and Youth Clinic, Atlanta, Georgia

Wayne Pediatric Clinic, Detroit, Michigan

Bellevue Hospital, New York, New York

Duke Children's Health Center, Pediatric Infectious Diseases, Durham, North Carolina

St. Christopher's Hospital for Children/Section of Immunology, Philadelphia, Pennsylvania

St. Jude Children's Research Hospital, Memphis, Tennessee

Department of Paediatrics and Child Health, Bloemfontein, Not set

Be Part Ypluntu Centre, Cape Town, Not set

FAMCRU, Ward J8, CapeTown, Not set

Dr. J Fourie Medical Centre, Dundee, Not set

Enhancing Care Foundation, Durban International Clinical Research Site, Durban, Not set

Wits RHI Shandukani Research Centre, Wits Reproductive Health & HIV Institute, Johannesburg, Not set

Clinical HIV Research Unit(CHRU), Wits Health Consortium, Department of Medicine, University of the Witwatersrand, Johannesburg, Not set

Empilweni Service and Research Unit (ESRU), Johannesburg, Not set

VX Pharma(Pty) Ltd, Pretoria, Not set

Perinatal HIV Research Unit, Soweto, Not set

The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Not set

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Not set

Faculty of Medicine, Khon Kaen University, Khon Kaen, Not set

Joint Clinical Research Centre, Kampala, Not set

Makerere University, Johns Hopkins (MU-JHU) Research Collaboration, Kampala, Not set

Baylor College of Medicine Children's Foundation - Uganda, Kampala, Not set

Conditions: HIV-1 Infection

Learn More ›

A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection

NCT05582694

Recruiting

Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, and the infection cannot be treated. Untreated HIV infection can make people more vulnerable to other infections as well as some cancers. Better treatments are needed for people with drug-resistant HIV. Objective: To see if a study drug (UB-421) is effective in people with drug-resistant HIV. Eligibility: People ag... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

09/15/2023

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection

Learn More ›

1 - 3 of 3